Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

BMC cancer - 19 Apr 2017

Chiba Masato, Togashi Yosuke, Bannno Eri, Kobayashi Yoshihisa, Nakamura Yu, Hayashi Hidetoshi, Terashima Masato, De Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Mitsudomi Tetsuya, Nishio Kazuto

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Databases, Genetic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Conformation

Share to Molecular Structure

Share to Protein Kinase Inhibitors

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 28424065
DOI: 10.1186/s12885-017-3263-z
PMCID: PMC5395747

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.PMID 28424065Read ↗

Patients with uncommon EGFR mutations also benefit from first-line osimertinib.Semantic proximity Read ↗

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.Semantic proximity Read ↗

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.Semantic proximity Read ↗

Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroSemantic proximity Read ↗

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR MutationsSemantic proximity Read ↗

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.Semantic proximity Read ↗

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Semantic proximity Read ↗

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.Semantic proximity Read ↗

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.Semantic proximity Read ↗

Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.